NantKwest to Present Data at the 59th Annual Meeting of the American Society of Hematology
December 04 2017 - 8:00AM
Business Wire
Oral Presentation to Highlight Preclinical
Data on a Chimeric Antigen Receptor (CAR) Engineered Natural Killer
Cell Therapy (CD19.taNK) in CD Resistant B-Cell Non-Hodgkin
Lymphoma
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases,
today announced an oral presentations will be given at the upcoming
59th Annual Meeting of the American Society of Hematology (ASH) in
Atlanta, Georgia on Saturday, December 9, 2017.
Presentation Title
CD19-Chimeric Antigen Receptor (CAR) Engineered Natural Killer
(NK) Cell Therapy: Novel “Off the Shelf” Immunotherapy in CD20
Resistant B-Cell Non-Hodgkin Lymphoma (NHL) Cell Lines, Primary NHL
Cells, and a Human Lymphoma Xenograft Model Target Activated
Natural Killer (CD19.taNK) Cellular Therapy: A Novel
Immunotherapeutic Approach to the Treatment of Non-Hodgkin Lymphoma
(NHL)
Abstract #110:
https://ash.confex.com/ash/2017/webprogram/Paper107066.html
Presenter: Sneha Purvey, MD, Department of Hematology and
Oncology, Tufts Medical Center, Boston, MA
Date: Saturday, December 9, 2017, 9:45AM, Building C,
Level 1, C101 Auditorium (Georgia World Congress Center)
Presentation Summary
This oral presentation will present preclinical data on the
company’s CD19.taNK program. CD19.taNK cell therapy is based on the
use of engineered NK cells expressing a human anti-CD19 CAR that
target CD19 expressing cells. The study was designed to more deeply
understand the mechanism of action associated with NK-based therapy
in B cell NHL and determine the potential for CD19.taNK cells as an
“off the shelf” therapy.
The study author’s identified high levels of NK activating
ligands indicative of a conserved mechanistic response to CD19-CAR
NK cell therapy. In addition, the authors determined that CD19.taNK
cell therapy induced significant single-agent cytolytic activity
against a wide range NHL cells, including primary DLBCL cells, and
cells resistant to standard anti-CD20 antibody.
“CD20 targeted antibody therapy represent one of the most
effective and widely used therapeutic interventions in blood
cancers. However, resistance is common, occurring in a large
percentage of patients,” said Patrick Soon-Shiong, MD, Chairman and
CEO of NantKwest. “For next generation therapies, such as our
CD19.taNK cell therapy, circumventing resistance requires both a
deeper understanding of the mechanisms of resistance and the
mechanisms of action. We believe these study results provide
encouraging data elucidating the significant, single-agent
cytolytic activity of CD19.taNK cell therapy and takes us one step
closer in our focus to transition this novel NK cell therapy to
clinical cancer care.”
About NantKwest
NantKwest (Nasdaq:NK) is a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases. NK
cells are the body’s first line of defense due to the innate
ability of NK cells to rapidly identify and destroy cells under
stress, such as cancer or virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to
grow active killer cells as a biological cancer therapy, has been
designed to induce cell death against cancer or infected cells by
three different modes of action: (1) Direct killing using activated
NK cells (aNK) that release toxic granules directly into the cell
through cell to cell contact, (2) Antibody-mediated killing using
haNKs, which are NK cells engineered to incorporate a high affinity
receptor that binds to an administered antibody, enhancing the
cancer cell killing effect of that antibody, and (3) Targeted
activated killing using taNKs, which are NK cells engineered to
incorporate chimeric antigen receptors (CARs) to target
tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of
T cell therapies including the reduction of risk of serious
"cytokine storms" reported after T cell therapy. As an
“off-the-shelf” therapy, NantKwest's NK cells do not rely on a
patient’s own often compromised immune system. In Phase 1 clinical
trials in patients with late stage cancer, NantKwest's NK cells
have been successfully administered as an outpatient infusion
therapy without any reported severe side effects, even at doses of
10 billion cells.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs that
include a Phase 2 trial for a rare form of melanoma and the planned
initiation of a clinical trial of NK cells targeted to breast
cancer, we believe NantKwest is uniquely positioned to be the
premier immunotherapy company and transform medicine by delivering
living drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care. For more information please
visit www.nantkwest.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171204005355/en/
NantKwest Inc.Jen Hodson, 562-397-3639jhodson@nantworks.com
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Apr 2023 to Apr 2024